person · Reporting owner

Sharp Shalini

Disclosed activity across 12 companies

Tapewire entity: 34427
SEC CIK: 0001377202

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
AGENUS INCAGEN · Entity 5774	Director	March 02, 2018	June 22, 2018
BeOne Medicines Ltd.ONC · Entity 2168	Director	June 11, 2026	June 15, 2026
Iambic Therapeutics, Inc.IAM · Entity 184417	Director	October 14, 2026	October 14, 2026
NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655	Director	May 27, 2026	May 29, 2026
Organon & Co.OGN · Entity 4115	Director	June 12, 2026	June 15, 2026
PRECISION BIOSCIENCES INCDTIL · Entity 6284	Director	May 10, 2021	May 12, 2021
SUTRO BIOPHARMA, INC.STRO · Entity 5797	Director	June 06, 2022	June 08, 2022
Septerna, Inc.SEPN · Entity 2452	Director	June 26, 2026	June 30, 2026
Ultragenyx Pharmaceutical Inc.RARE · Entity 4337	EVP, Finance	October 14, 2020	October 16, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

AGENUS INC

Report date March 02, 2018 · Filed June 22, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option, right to buySEC Table II · derivative / convertible security · Conversion / exercise price $5.65 · Expires 2028-03-02	Direct	18,533	Reported balance After 2018-03-02 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2018-03-02 · Grant · Acquired 18,533 · Balance 18,533
Stock Option, right to buySEC Table II · derivative / convertible security · Conversion / exercise price $5.65 · Expires 2028-03-02	Direct	37,500	Reported balance After 2018-06-20 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-06-20 · Grant · Acquired 37,500 · Balance 37,500 F1: Option was granted on March 2, 2018 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 20, 2018. Option awarded in accordance with the Agenus Inc. Amended and Restated 2009 Equity Incentive Plan, vesting on March 2, 2019
Stock Option, right to buySEC Table II · derivative / convertible security · Conversion / exercise price $2.50 · Expires 2028-06-21	Direct	10,000	Reported balance After 2018-06-21 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-06-21 · Grant · Acquired 10,000 · Balance 10,000

Filing footnotes · ownership attribution and instrument terms

F1: Option was granted on March 2, 2018 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 20, 2018. Option awarded in accordance with the Agenus Inc. Amended and Restated 2009 Equity Incentive Plan, vesting on March 2, 2019

BeOne Medicines Ltd.

Report date June 11, 2026 · Filed June 15, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	38,116	Reported balance After 2026-06-11 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-06-11 · Grant · Acquired 18,980 · Balance 38,116 F1: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless there is a triggering event of accelerated vesting pursuant to the Company's Independent Non-Executive Director Compensation Policy.
American Depositary SharesSEC Table I · non-derivative	Direct	9	Reported balance Holding disclosure · report date 2026-06-11 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 9 F2: Each American Depositary Share represents 13 Ordinary Shares.

Filing footnotes · ownership attribution and instrument terms

F1: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless there is a triggering event of accelerated vesting pursuant to the Company's Independent Non-Executive Director Compensation Policy.

F2: Each American Depositary Share represents 13 Ordinary Shares.

Iambic Therapeutics, Inc.

Report date October 14, 2026 · Filed October 14, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.73 · Expires 2035-12-02	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-10-14 · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · Balance Not disclosed F1: Twenty-five percent of the shares subject to the option vested on September 25, 2026 and 1/48th of the shares vest monthly thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: Twenty-five percent of the shares subject to the option vested on September 25, 2026 and 1/48th of the shares vest monthly thereafter.

NEUROCRINE BIOSCIENCES INC

Report date May 27, 2026 · Filed May 29, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restriced Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	2,567	Reported balance After 2026-05-27 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-27 · Grant · Acquired 2,567 · Balance 2,567 F1: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2: The RSUs will vest in full on May 27, 2027.

Filing footnotes · ownership attribution and instrument terms

F1: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.

F2: The RSUs will vest in full on May 27, 2027.

Organon & Co.

Report date June 12, 2026 · Filed June 15, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Phantom StockSEC Table II · derivative / convertible security	Direct	81,495.885	Reported balance After 2026-06-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-12 · Grant · Acquired 17,857.143 · Balance 81,495.885 F1: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3: Holdings include phantom stock acquired in dividend reinvestment transactions on September 11, 2025, December 11, 2025, March 12, 2026 and June 11, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1.

F2: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan.

F3: Holdings include phantom stock acquired in dividend reinvestment transactions on September 11, 2025, December 11, 2025, March 12, 2026 and June 11, 2026.

PRECISION BIOSCIENCES INC

Report date May 10, 2021 · Filed May 12, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.07 · Expires 2031-05-09	Direct	32,800	Reported balance After 2021-05-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-05-10 · Grant · Acquired 32,800 · Balance 32,800 F1: The option vests on the earlier of May 10, 2022 or the day immediately prior to the date of the next annual meeting of the Company's stockholders occurring after May 10, 2021, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests on the earlier of May 10, 2022 or the day immediately prior to the date of the next annual meeting of the Company's stockholders occurring after May 10, 2021, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.

SUTRO BIOPHARMA, INC.

Report date June 06, 2022 · Filed June 08, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.44 · Expires 2032-06-05	Direct	18,500	Reported balance After 2022-06-06 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-06-06 · Grant · Acquired 18,500 · Balance 18,500 F1: The option vests as to 8.33% of the total shares monthly, commencing July 6, 2022, with 100% of the total shares vested and exercisable on the earlier of the issuer's 2023 annual stockholders meeting or June 6, 2023, subject to the reporting person's provision of service to the issuer on each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests as to 8.33% of the total shares monthly, commencing July 6, 2022, with 100% of the total shares vested and exercisable on the earlier of the issuer's 2023 annual stockholders meeting or June 6, 2023, subject to the reporting person's provision of service to the issuer on each vesting date.

Septerna, Inc.

Report date June 26, 2026 · Filed June 30, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.34 · Expires 2036-06-25	Direct	15,000	Reported balance After 2026-06-26 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-26 · Grant · Acquired 15,000 · Balance 15,000 F1: The shares underlying the stock option vest in full upon the earlier of (i) June 26, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying the stock option vest in full upon the earlier of (i) June 26, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date.

Ultragenyx Pharmaceutical Inc.

Report date October 14, 2020 · Filed October 16, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	97,812	Reported balance After 2020-10-14 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2020-10-14 · Sale · Disposed 375 · Balance 97,812 F1: Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). F2: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs").

F2: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ARRAY BIOPHARMA INC

Report date July 30, 2019 · Filed July 30, 2019

Section 16 reporting ended · disclosed 2019-07-30. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2019-07-30 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2019-07-30 · Disposition to issuer · Disposed 5,000 · Balance 5,000 F1: On June 14, 2019, Array BioPharma Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Pfizer Inc. ("Pfizer") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer ("Purchaser"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F2: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. Row 2 · 2019-07-30 · Disposition to issuer · Disposed 5,000 · Balance 0 F1: On June 14, 2019, Array BioPharma Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Pfizer Inc. ("Pfizer") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer ("Purchaser"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F2: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F3: Represents shares of Company common stock underlying each restricted stock unit (a "Company RSU") held by the Reporting Person, whether or not vested. Pursuant to the terms of the Merger Agreement, each Company RSU held by the Reporting Person was converted into the right to receive an amount in cash equal to the product of (i) $48.00 and (ii) the number of shares of Company common stock subject to such Company RSU.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.70 · Expires 2027-04-27	Direct	Reported balance After 2019-07-30 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-07-30 · Disposition to issuer · Disposed 25,000 · Balance 0 F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F4: The option provided for vesting in four equal annual installments beginning on April 27, 2018.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.47 · Expires 2027-10-26	Direct	Reported balance After 2019-07-30 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-07-30 · Disposition to issuer · Disposed 25,000 · Balance 0 F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F6: The option provided for vesting in four equal annual installments beginning on October 26, 2018.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.55 · Expires 2028-10-25	Direct	Reported balance After 2019-07-30 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2019-07-30 · Disposition to issuer · Disposed 25,000 · Balance 0 F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F7: The option provided for vesting in four equal annual installments beginning on October 25, 2019.

Filing footnotes · ownership attribution and instrument terms

F1: On June 14, 2019, Array BioPharma Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Pfizer Inc. ("Pfizer") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer ("Purchaser"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes.

F2: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes.

F3: Represents shares of Company common stock underlying each restricted stock unit (a "Company RSU") held by the Reporting Person, whether or not vested. Pursuant to the terms of the Merger Agreement, each Company RSU held by the Reporting Person was converted into the right to receive an amount in cash equal to the product of (i) $48.00 and (ii) the number of shares of Company common stock subject to such Company RSU.

F4: The option provided for vesting in four equal annual installments beginning on April 27, 2018.

F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option.

F6: The option provided for vesting in four equal annual installments beginning on October 26, 2018.

F7: The option provided for vesting in four equal annual installments beginning on October 25, 2019.

Mirati Therapeutics, Inc.

Report date January 23, 2024 · Filed January 24, 2024

Section 16 reporting ended · disclosed 2024-01-24. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2024-01-23 transaction · row 3 3 source rows · reconciled sequence Row 1 · 2024-01-23 · Disposition to issuer · Disposed 4,162 · Balance 12,060 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 8, 2023, among the Issuer, Bristol-Myers Squibb Company ("BMS"), and Vineyard Merger Sub Inc., a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of January 23, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of BMS. F2: At the Effective Time, each issued and outstanding share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was converted into the right to receive (A) $58.00 per share in cash (the "Closing Consideration") and (B) one contingent value right (a "CVR"), which represents the right to receive the Milestone Payment (as such term is defined in the CVR Agreement, which is itself defined in the Merger Agreement) (the consideration contemplated by (A) and (B), together, the "Merger Consideration"), without interest and subject to any withholding taxes. Row 2 · 2024-01-23 · Disposition to issuer · Disposed 5,252 · Balance 6,808 F3: Pursuant to the Merger Agreement, at the Effective Time, each of these restricted stock units ("RSUs") that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration in respect of each such RSU. Row 3 · 2024-01-23 · Disposition to issuer · Disposed 6,808 · Balance 0 F4: Pursuant to the Merger Agreement and the Company Equity Plans (as such term is defined in the Merger Agreement), at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive a cash award of BMS in an amount equal to the product of the number of restricted stock units subject to such RSU immediately prior to the Effective Time and the last trading price of a share of Company Common Stock before the Effective Time (the "Converted Cash Award"). Following the Effective Time, the Converted Cash Award will be subject to the same terms and conditions applicable to such Issuer RSUs, including with respect to vesting.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $45.66 · Expires 2033-01-20	Direct	0	Reported balance After 2024-01-23 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-01-23 · Disposition to issuer · Disposed 7,520 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting).

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 8, 2023, among the Issuer, Bristol-Myers Squibb Company ("BMS"), and Vineyard Merger Sub Inc., a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of January 23, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of BMS.

F2: At the Effective Time, each issued and outstanding share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was converted into the right to receive (A) $58.00 per share in cash (the "Closing Consideration") and (B) one contingent value right (a "CVR"), which represents the right to receive the Milestone Payment (as such term is defined in the CVR Agreement, which is itself defined in the Merger Agreement) (the consideration contemplated by (A) and (B), together, the "Merger Consideration"), without interest and subject to any withholding taxes.

F3: Pursuant to the Merger Agreement, at the Effective Time, each of these restricted stock units ("RSUs") that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration in respect of each such RSU.

F4: Pursuant to the Merger Agreement and the Company Equity Plans (as such term is defined in the Merger Agreement), at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive a cash award of BMS in an amount equal to the product of the number of restricted stock units subject to such RSU immediately prior to the Effective Time and the last trading price of a share of Company Common Stock before the Effective Time (the "Converted Cash Award"). Following the Effective Time, the Converted Cash Award will be subject to the same terms and conditions applicable to such Issuer RSUs, including with respect to vesting.

F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting).

Nuvation Bio Inc.

Report date February 10, 2021 · Filed February 27, 2021

Section 16 reporting ended · disclosed 2021-02-27. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	35,000	Ending reported balance After 2021-02-10 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2021-02-10 · Exercise / conversion · Acquired 25,000 · Balance 25,000 F1: Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (such transaction, the "Business Combination"), was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date. Row 2 · 2021-02-10 · Grant · Acquired 10,000 · Balance 35,000 F2: Acquired pursuant to one of a number of subscription agreements that Panacea entered into with various investors pursuant to which such investors agreed to purchase, immediately prior to the closing of the Business Combination, an aggregate of 47,655,000 shares of Class A Common Stock at a price of $10.00 per share.
Class B Common StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2021-02-10 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-02-10 · Exercise / conversion · Disposed 25,000 · Balance 0 F1: Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (such transaction, the "Business Combination"), was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (such transaction, the "Business Combination"), was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date.

F2: Acquired pursuant to one of a number of subscription agreements that Panacea entered into with various investors pursuant to which such investors agreed to purchase, immediately prior to the closing of the Business Combination, an aggregate of 47,655,000 shares of Class A Common Stock at a price of $10.00 per share.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 26, 2026 Filed Jun 30, 2026 23:00 UTC	Septerna, Inc. SEPN · Entity 2452	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $37.34	$0.00	Disclosure SEC source: 0001193125-26-291055 · ownership.xml · derivative · entry 1 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2036-06-25 F1 · derivative.exercise_date: The shares underlying the stock option vest in full upon the earlier of (i) June 26, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date. Read SEC document
June 12, 2026 Filed Jun 15, 2026 20:41 UTC	Organon & Co. OGN · Entity 4115	GrantPhantom Stock · Derivative	17,857.143	$13.44	$240,000.00	Disclosure SEC source: 0001628280-26-043256 · wk-form4_1781556099.xml · derivative · entry 1 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,495.885 Underlying: Common Stock · 17,857.143 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on September 11, 2025, December 11, 2025, March 12, 2026 and June 11, 2026. Read SEC document
June 11, 2026 Filed Jun 15, 2026 21:49 UTC	BeOne Medicines Ltd. ONC · Entity 2168	GrantOrdinary Shares	18,980	$0.00	$0.00	Disclosure SEC source: 0001377202-26-000007 · wk-form4_1781560173.xml · nonDerivative · entry 1 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,116 F1 · security: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless there is a triggering event of accelerated vesting pursuant to the Company's Independent Non-Executive Director Compensation Policy. Read SEC document
May 27, 2026 Filed May 29, 2026 22:03 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	GrantRestriced Stock Unit · Derivative	2,567	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001377202-26-000006 · wk-form4_1780092209.xml · derivative · entry 1 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,567 Underlying: Common Stock · 2,567 shares Expires not disclosed F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: The RSUs will vest in full on May 27, 2027. F2 · derivative.expiration_date: The RSUs will vest in full on May 27, 2027. Read SEC document
May 21, 2026 Filed May 21, 2026 23:24 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionRestricted Stock Unit · Derivative	1,659	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001377202-26-000004 · wk-form4_1779405862.xml · derivative · entry 2 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,659 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: This RSU award was granted to the Reporting Person on May 21, 2025 and is fully vested. F2 · derivative.expiration_date: This RSU award was granted to the Reporting Person on May 21, 2025 and is fully vested. Read SEC document
May 21, 2026 Filed May 21, 2026 23:24 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionCommon Stock	1,659	$0.00	$0.00	Disclosure SEC source: 0001377202-26-000004 · wk-form4_1779405862.xml · nonDerivative · entry 1 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,088 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 17, 2025 Filed Jun 20, 2025 22:44 UTC	Septerna, Inc. SEPN · Entity 2452	GrantStock Option (Right to Buy) · Derivative	16,623	$0.00 Strike: $10.24	$0.00	Disclosure SEC source: 0000950170-25-088622 · ownership.xml · derivative · entry 1 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,623 Underlying: Common Stock · 16,623 shares Expires 2035-06-16 F1 · derivative.exercise_date: The shares underlying the stock option will vest in full upon the earlier of (i) June 17, 2026 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date. Read SEC document
June 13, 2025 Filed Jun 16, 2025 21:34 UTC	Organon & Co. OGN · Entity 4115	GrantPhantom Stock · Derivative	23,904.382	$10.04	$240,000.00	Disclosure SEC source: 0001821825-25-000055 · wk-form4_1750109646.xml · derivative · entry 1 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,054.148 Underlying: Common Stock · 23,904.382 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock units acquired in dividend reinvestment transactions on June 13, 2024, September 12, 2024, December 12, 2024, March 13, 2025 and June 12, 2025. Read SEC document
May 22, 2025 Filed May 22, 2025 21:28 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionRestricted Stock Unit · Derivative	1,435	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000914475-25-000131 · wk-form4_1747949275.xml · derivative · entry 4 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,435 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F4 · derivative.exercise_date: This RSU award was granted to the Reporting Person on May 22, 2024 and is fully vested. F4 · derivative.expiration_date: This RSU award was granted to the Reporting Person on May 22, 2024 and is fully vested. Read SEC document
May 22, 2025 Filed May 22, 2025 21:28 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionCommon Stock	1,435	$0.00	$0.00	Disclosure SEC source: 0000914475-25-000131 · wk-form4_1747949275.xml · nonDerivative · entry 1 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,429 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 21, 2025 Filed May 22, 2025 21:28 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	GrantNon-Qualified Stock Option · Derivative	3,305	$0.00 Strike: $120.56	$0.00	Disclosure SEC source: 0000914475-25-000131 · wk-form4_1747949275.xml · derivative · entry 3 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,305 Underlying: Common Stock · 3,305 shares Expires 2035-05-21 F3 · derivative.exercise_date: Option vests in 12 monthly installments beginning June 21, 2025. Read SEC document
May 21, 2025 Filed May 22, 2025 21:28 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	GrantRestricted Stock Unit · Derivative	1,659	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000914475-25-000131 · wk-form4_1747949275.xml · derivative · entry 2 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,659 Underlying: Common Stock · 1,659 shares Expires not disclosed F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: The RSUs will vest in full on May 21, 2026. F2 · derivative.expiration_date: The RSUs will vest in full on May 21, 2026. Read SEC document
May 21, 2025 Filed May 22, 2025 23:47 UTC	BeOne Medicines Ltd. BGNE · Entity 2168	GrantShare Option (Right to Buy) · Derivative	22,750	$0.00 Strike: $18.19	$0.00	Disclosure SEC source: 0001651308-25-000090 · wk-form4_1747957614.xml · derivative · entry 2 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,750 Underlying: Ordinary Shares · 22,750 shares Expires 2035-05-20 F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F3 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended. Read SEC document
May 21, 2025 Filed May 22, 2025 23:47 UTC	BeOne Medicines Ltd. BGNE · Entity 2168	GrantOrdinary Shares	10,985	$0.00	$0.00	Disclosure SEC source: 0001651308-25-000090 · wk-form4_1747957614.xml · nonDerivative · entry 1 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,136 F1 · security: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The restricted share units were granted under the Company's Independent Director Compensation Policy, as amended. Read SEC document
September 30, 2024 Filed Oct 2, 2024 23:21 UTC	BeOne Medicines Ltd. BGNE · Entity 2168	GrantShare Option (Right to Buy) · Derivative	17,238	$0.00 Strike: $17.27	$0.00	Disclosure SEC source: 0001651308-24-000131 · wk-form4_1727911273.xml · derivative · entry 2 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,238 Underlying: Ordinary Shares · 17,238 shares Expires 2034-09-29 F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F2 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F3 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended. Read SEC document
September 30, 2024 Filed Oct 2, 2024 23:21 UTC	BeOne Medicines Ltd. BGNE · Entity 2168	GrantOrdinary Shares	8,151	$0.00	$0.00	Disclosure SEC source: 0001651308-24-000131 · wk-form4_1727911273.xml · nonDerivative · entry 1 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,151 F1 · security: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The restricted share units were granted under the Company's Independent Director Compensation Policy, as amended. Read SEC document
June 07, 2024 Filed Jun 11, 2024 19:17 UTC	Organon & Co. OGN · Entity 4115	GrantPhantom Stock · Derivative	9,638.554	$20.75	$200,000.00	Disclosure SEC source: 0001821825-24-000079 · wk-form4_1718133465.xml · derivative · entry 1 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,783.9 Underlying: Common Stock · 9,638.554 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on June 15, 2023, September 14, 2023, December 14, 2023 and March 14, 2024. Read SEC document
May 22, 2024 Filed May 23, 2024 22:34 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	GrantNon-Qualified Stock Option · Derivative	2,982	$0.00 Strike: $139.43	$0.00	Disclosure SEC source: 0000914475-24-000154 · wk-form4_1716503634.xml · derivative · entry 2 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,982 Underlying: Common Stock · 2,982 shares Expires 2034-05-22 F3 · derivative.exercise_date: Option vests in 12 monthly installments beginning June 22, 2024. Read SEC document
May 22, 2024 Filed May 23, 2024 22:34 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	GrantRestricted Stock Unit · Derivative	1,435	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000914475-24-000154 · wk-form4_1716503634.xml · derivative · entry 1 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,435 Underlying: Common Stock · 1,435 shares Expires not disclosed F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: The RSUs will vest in full on May 22, 2025. F2 · derivative.expiration_date: The RSUs will vest in full on May 22, 2025. Read SEC document
May 17, 2024 Filed May 21, 2024 21:35 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionRestricted Stock Unit · Derivative	2,100	$0.00	$0.00	Disclosure SEC source: 0000914475-24-000138 · wk-form4_1716327316.xml · derivative · entry 3 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,100 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F4 · derivative.exercise_date: This RSU award was granted to the Reporting Person on May 17, 2023 and is fully vested. F4 · derivative.expiration_date: This RSU award was granted to the Reporting Person on May 17, 2023 and is fully vested. Read SEC document
May 17, 2024 Filed May 21, 2024 21:35 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	SaleCommon Stock	1,106	$141.90	$156,943.39	Disclosure SEC source: 0000914475-24-000138 · wk-form4_1716327316.xml · nonDerivative · entry 2 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 994 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $140.81 to $142.33. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range Read SEC document
May 17, 2024 Filed May 21, 2024 21:35 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionCommon Stock	2,100	$0.00	$0.00	Disclosure SEC source: 0000914475-24-000138 · wk-form4_1716327316.xml · nonDerivative · entry 1 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 23, 2024 Filed Jan 24, 2024 01:38 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Disposition to issuerOption to Purchase Common Stock · Derivative	7,520	Not disclosed Strike: $45.66	Not disclosed	Disclosure SEC source: 0001140361-24-003537 · form4.xml · derivative · entry 4 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,520 shares Expires 2033-01-20 F5 · price: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). Read SEC document
January 23, 2024 Filed Jan 24, 2024 01:38 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Disposition to issuerCommon Stock	6,808	Not disclosed	Not disclosed	Disclosure SEC source: 0001140361-24-003537 · form4.xml · nonDerivative · entry 3 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F4 · price: Pursuant to the Merger Agreement and the Company Equity Plans (as such term is defined in the Merger Agreement), at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive a cash award of BMS in an amount equal to the product of the number of restricted stock units subject to such RSU immediately prior to the Effective Time and the last trading price of a share of Company Common Stock before the Effective Time (the "Converted Cash Award"). Following the Effective Time, the Converted Cash Award will be subject to the same terms and conditions applicable to such Issuer RSUs, including with respect to vesting. Read SEC document
January 23, 2024 Filed Jan 24, 2024 01:38 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Disposition to issuerCommon Stock	5,252	Not disclosed	Not disclosed	Disclosure SEC source: 0001140361-24-003537 · form4.xml · nonDerivative · entry 2 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,808 F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each of these restricted stock units ("RSUs") that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration in respect of each such RSU. Read SEC document
January 23, 2024 Filed Jan 24, 2024 01:38 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Disposition to issuerCommon Stock	4,162	Not disclosed	Not disclosed	Disclosure SEC source: 0001140361-24-003537 · form4.xml · nonDerivative · entry 1 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,060 F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 8, 2023, among the Issuer, Bristol-Myers Squibb Company ("BMS"), and Vineyard Merger Sub Inc., a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of January 23, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of BMS. F2 · price: At the Effective Time, each issued and outstanding share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was converted into the right to receive (A) $58.00 per share in cash (the "Closing Consideration") and (B) one contingent value right (a "CVR"), which represents the right to receive the Milestone Payment (as such term is defined in the CVR Agreement, which is itself defined in the Merger Agreement) (the consideration contemplated by (A) and (B), together, the "Merger Consideration"), without interest and subject to any withholding taxes. Read SEC document
December 29, 2023 Filed Jan 3, 2024 23:24 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	GrantCommon Stock	6,808	$58.75	$399,970.00	Disclosure SEC source: 0001628280-24-000302 · wk-form4_1704324252.xml · nonDerivative · entry 1 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,222 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date. Read SEC document
June 09, 2023 Filed Jun 13, 2023 21:00 UTC	Organon & Co. OGN · Entity 4115	GrantPhantom Stock · Derivative	10,086	$19.83	$200,005.38	Disclosure SEC source: 0001209191-23-036798 · doc4.xml · derivative · entry 2 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,594 Underlying: Common Stock · 10,086 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on June 16, 2022, September 15, 2022, December 15, 2022 and March 16, 2023. Read SEC document
May 17, 2023 Filed May 19, 2023 21:22 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	GrantRestricted Stock Unit · Derivative	2,100	$0.00	$0.00	Disclosure SEC source: 0001209191-23-031127 · doc4.xml · derivative · entry 2 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,100 Underlying: Common Stock · 2,100 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units will vest in full on May 17, 2024. F3 · derivative.expiration_date: The Restricted Stock Units will vest in full on May 17, 2024. Read SEC document
May 17, 2023 Filed May 19, 2023 21:22 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	GrantNon-Qualified Stock Option · Derivative	4,290	$0.00 Strike: $95.27	$0.00	Disclosure SEC source: 0001209191-23-031127 · doc4.xml · derivative · entry 1 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,290 Underlying: Common Stock · 4,290 shares Expires 2033-05-17 F1 · derivative.exercise_date: Option vests in 12 monthly installments beginning June 17, 2023. Read SEC document
January 20, 2023 Filed Jan 24, 2023 21:03 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	GrantNon Qualified Stock Option (right to buy) · Derivative	7,520	$0.00 Strike: $45.66	$0.00	Disclosure SEC source: 0001214659-23-001038 · marketforms-58261.xml · derivative · entry 2 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,520 Underlying: Common Stock · 7,520 shares Expires 2033-01-20 F2 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. Read SEC document
January 20, 2023 Filed Jan 24, 2023 21:03 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	GrantCommon Stock	4,444	$0.00	$0.00	Disclosure SEC source: 0001214659-23-001038 · marketforms-58261.xml · nonDerivative · entry 1 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,414 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date. Read SEC document
June 10, 2022 Filed Jun 14, 2022 23:42 UTC	Organon & Co. OGN · Entity 4115	GrantPhantom Stock · Derivative	5,640	$35.46	$199,994.40	Disclosure SEC source: 0001104659-22-071143 · tm2218336-11_4seq1.xml · derivative · entry 2 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,935 Underlying: Common Stock · 5,640 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on September 13, 2021, December 16, 2021 and March 17, 2022. Read SEC document
June 06, 2022 Filed Jun 8, 2022 23:10 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	GrantStock Option (right to buy) · Derivative	18,500	$0.00 Strike: $4.44	$0.00	Disclosure SEC source: 0001209191-22-035212 · doc4.xml · derivative · entry 1 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,500 Underlying: Common Stock · 18,500 shares Expires 2032-06-05 F1 · derivative.exercise_date: The option vests as to 8.33% of the total shares monthly, commencing July 6, 2022, with 100% of the total shares vested and exercisable on the earlier of the issuer's 2023 annual stockholders meeting or June 6, 2023, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document
May 18, 2022 Filed May 20, 2022 20:16 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	GrantNon-Qualified Stock Option · Derivative	9,724	$0.00 Strike: $84.95	$0.00	Disclosure SEC source: 0001209191-22-030998 · doc4.xml · derivative · entry 1 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,724 Underlying: Common Stock · 9,724 shares Expires 2032-05-18 F1 · derivative.exercise_date: Option vests in 12 monthly installments beginning June 18, 2022. Read SEC document
January 14, 2022 Filed Jan 18, 2022 23:17 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	GrantNon Qualified Stock Option (right to buy) · Derivative	3,688	$0.00 Strike: $124.31	$0.00	Disclosure SEC source: 0001214659-22-000841 · marketforms-55084.xml · derivative · entry 2 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,688 Underlying: Common Stock · 3,688 shares Expires 2032-01-13 F2 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. Read SEC document
January 14, 2022 Filed Jan 18, 2022 23:17 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	GrantCommon Stock	2,546	$0.00	$0.00	Disclosure SEC source: 0001214659-22-000841 · marketforms-55084.xml · nonDerivative · entry 1 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,970 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date. Read SEC document
June 04, 2021 Filed Jun 9, 2021 00:31 UTC	Organon & Co. OGN · Entity 4115	GrantPhantom Stock · Derivative	9,061	$36.05	$326,649.05	Disclosure SEC source: 0000899243-21-022669 · doc4.xml · derivative · entry 2 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,061 Underlying: Common Stock · 9,061 shares Expires not disclosed F2 · derivative.exercise_price: 1-for-1 F3 · derivative.exercise_date: Consists of (i) a one-time grant of 5,549 phantom units awarded in connection with the Separation, which units will vest in full on the earlier of the one-year anniversary of the Separation or Organon's first annual shareholders meeting after the Separation, and (ii) a pro-rata portion of the annual equity retainer in the form of 3,512 phantom units, which units are fully vested. Phantom units are granted under the Organon Non-Employee Director Savings Plan and are payable in cash upon settlement no sooner than one year after service as a director ceases. F3 · derivative.expiration_date: Consists of (i) a one-time grant of 5,549 phantom units awarded in connection with the Separation, which units will vest in full on the earlier of the one-year anniversary of the Separation or Organon's first annual shareholders meeting after the Separation, and (ii) a pro-rata portion of the annual equity retainer in the form of 3,512 phantom units, which units are fully vested. Phantom units are granted under the Organon Non-Employee Director Savings Plan and are payable in cash upon settlement no sooner than one year after service as a director ceases. Read SEC document
June 03, 2021 Filed Jun 7, 2021 21:07 UTC	SUTRO BIOPHARMA, INC. STRO · Entity 5797	GrantStock Option (right to buy) · Derivative	18,500	$0.00 Strike: $18.21	$0.00	Disclosure SEC source: 0001209191-21-038699 · doc4.xml · derivative · entry 1 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,500 Underlying: Common Stock · 18,500 shares Expires 2031-06-02 F1 · derivative.exercise_date: The option vests as to 8.33% of the total shares monthly, commencing July 3, 2021, with 100% of the total shares vested and exercisable on the earlier of the issuer's 2022 annual stockholders meeting or June 3, 2022, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document
May 19, 2021 Filed May 20, 2021 20:12 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	GrantNon-Qualified Stock Option · Derivative	8,833	$0.00 Strike: $92.35	$0.00	Disclosure SEC source: 0001209191-21-034395 · doc4.xml · derivative · entry 1 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,833 Underlying: Common Stock · 8,833 shares Expires 2031-05-19 F1 · derivative.exercise_date: Option vests in 12 equal monthly installments beginning June 19, 2021. Read SEC document
May 10, 2021 Filed May 12, 2021 20:09 UTC	PRECISION BIOSCIENCES INC DTIL · Entity 6284	GrantStock Option (Right to Buy) · Derivative	32,800	$0.00 Strike: $8.07	$0.00	Disclosure SEC source: 0001209191-21-032025 · doc4.xml · derivative · entry 1 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,800 Underlying: Common Stock · 32,800 shares Expires 2031-05-09 F1 · derivative.exercise_date: The option vests on the earlier of May 10, 2022 or the day immediately prior to the date of the next annual meeting of the Company's stockholders occurring after May 10, 2021, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document
March 26, 2021 Filed Mar 30, 2021 21:41 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	GrantNon Qualified Stock Option (right to buy) · Derivative	3,523	$0.00 Strike: $164.98	$0.00	Disclosure SEC source: 0001214659-21-003636 · marketforms-52136.xml · derivative · entry 2 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,523 Underlying: Common Stock · 3,523 shares Expires 2031-03-25 F2 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 36 equal monthly installments following the date of grant. Read SEC document
March 26, 2021 Filed Mar 30, 2021 21:41 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	GrantCommon Stock	2,424	$0.00	$0.00	Disclosure SEC source: 0001214659-21-003636 · marketforms-52136.xml · nonDerivative · entry 1 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,424 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 1/3rd annually on the anniversary of the grant date. Read SEC document
February 10, 2021 Filed Feb 27, 2021 00:02 UTC	Nuvation Bio Inc. NUVB · Entity 4384	Exercise / conversionClass B Common Stock · Derivative	25,000	$0.00	$0.00	Disclosure SEC source: 0001213900-21-012235 · ownership.xml · derivative · entry 3 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 25,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (such transaction, the "Business Combination"), was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date. F1 · derivative.exercise_date: Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (such transaction, the "Business Combination"), was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date. F1 · derivative.expiration_date: Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (such transaction, the "Business Combination"), was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date. Read SEC document
February 10, 2021 Filed Feb 27, 2021 00:02 UTC	Nuvation Bio Inc. NUVB · Entity 4384	GrantClass A Common Stock	10,000	$10.00	$100,000.00	Disclosure SEC source: 0001213900-21-012235 · ownership.xml · nonDerivative · entry 2 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 F2 · price: Acquired pursuant to one of a number of subscription agreements that Panacea entered into with various investors pursuant to which such investors agreed to purchase, immediately prior to the closing of the Business Combination, an aggregate of 47,655,000 shares of Class A Common Stock at a price of $10.00 per share. Read SEC document
February 10, 2021 Filed Feb 27, 2021 00:02 UTC	Nuvation Bio Inc. NUVB · Entity 4384	Exercise / conversionClass A Common Stock	25,000	$0.00	$0.00	Disclosure SEC source: 0001213900-21-012235 · ownership.xml · nonDerivative · entry 1 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (such transaction, the "Business Combination"), was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date. Read SEC document
October 14, 2020 Filed Oct 16, 2020 23:15 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	SaleCommon Stock	375	$87.99	$32,996.25	Disclosure SEC source: 0001209191-20-055172 · doc4.xml · nonDerivative · entry 1 Sharp Shalini · CIK 0001377202 · EVP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,812 F1 · shares: Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document
August 17, 2020 Filed Aug 19, 2020 18:11 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	Exercise / conversionStock Option (Right to Buy) · Derivative	3,669	$0.00 Strike: $48.43	$0.00	Disclosure SEC source: 0001209191-20-047455 · doc4.xml · derivative · entry 11 Sharp Shalini · CIK 0001377202 · CFO & Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,312 Underlying: Common Stock · 3,669 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 1/4th of the option vested one year from March 1, 2018 and then 1/48th of the option vested monthly thereafter. Read SEC document
August 17, 2020 Filed Aug 19, 2020 18:11 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	Exercise / conversionStock Option (Right to Buy) · Derivative	7,188	$0.00 Strike: $67.55	$0.00	Disclosure SEC source: 0001209191-20-047455 · doc4.xml · derivative · entry 10 Sharp Shalini · CIK 0001377202 · CFO & Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,812 Underlying: Common Stock · 7,188 shares Expires 2029-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/4th of the option vested one year from March 1, 2019 and then 1/48th of the option vested monthly thereafter. Read SEC document
August 17, 2020 Filed Aug 19, 2020 18:11 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	Exercise / conversionStock Option (Right to Buy) · Derivative	500	$0.00 Strike: $70.57	$0.00	Disclosure SEC source: 0001209191-20-047455 · doc4.xml · derivative · entry 9 Sharp Shalini · CIK 0001377202 · CFO & Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 500 shares Expires 2026-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4th of the option vested one year from June 1, 2016 and then 1/48th of the option vested monthly thereafter. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.